bluebird bio’s (BLUE) “Sector Perform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of bluebird bio (NASDAQ:BLUE) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $4.00 target price on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the company. JPMorgan Chase & Co. downgraded bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday. Wells Fargo & Company cut their price objective on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 25th. Bank of America downgraded bluebird bio from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $3.00 to $0.50 in a research report on Friday. Robert W. Baird cut their price target on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, August 15th. Finally, StockNews.com started coverage on shares of bluebird bio in a report on Sunday, November 10th. They set a “sell” rating for the company. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.03.

bluebird bio Trading Down 11.5 %

BLUE traded down $0.04 during trading on Friday, reaching $0.32. The company had a trading volume of 9,162,727 shares, compared to its average volume of 7,439,042. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. The business has a 50 day simple moving average of $0.49 and a 200-day simple moving average of $0.78. The stock has a market cap of $62.21 million, a P/E ratio of -0.14 and a beta of 0.76. bluebird bio has a 52 week low of $0.32 and a 52 week high of $5.53.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The firm had revenue of $18.57 million during the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. On average, equities analysts anticipate that bluebird bio will post -1.41 EPS for the current fiscal year.

Institutional Trading of bluebird bio

A number of hedge funds have recently bought and sold shares of BLUE. Allegheny Financial Group LTD purchased a new position in shares of bluebird bio in the 2nd quarter valued at $25,000. Verition Fund Management LLC purchased a new position in bluebird bio in the third quarter valued at about $42,000. Bayesian Capital Management LP bought a new position in bluebird bio in the first quarter worth about $52,000. SG Americas Securities LLC lifted its position in shares of bluebird bio by 152.4% during the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 74,185 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of bluebird bio by 113.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 29,113 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.